Atorvastatin in stroke: a review of SPARCL and subgroup analysis
Authors:
- Justin ZivinJZJustin Zivin
- Andrew B StemerASAndrew B Stemer
Open Access
- 1 March 2010
- journal article
- review article
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. 6, 229-236
Abstract
Peer reviewed article authored by (Branko N Huisa, Andrew B Stemer, Justin A Zivin). Read article or submit your manuscript for publishing.Keywords
This publication has 47 references indexed in Scilit:
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 2005
- Trends in the Leading Causes of Death in the United States, 1970-2002JAMA, 2005
- Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein CholesterolThe American Journal of Cardiology, 2005
- Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortalityNeurology, 2005
- Statin administration prior to ischaemic stroke onset and survival: exploratory evidence from matched treatment–control studyEuropean Journal of Neurology, 2005
- HMG-CoA Reductase Inhibitors Improve Acute Ischemic Stroke OutcomeStroke, 2005
- Neuroprotective effects of atorvastatin against glutamate‐induced excitotoxicity in primary cortical neuronesJournal of Neurochemistry, 2005
- Statins in Stroke Prevention and Carotid AtherosclerosisStroke, 2004
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range: Results of the Cholesterol and Recurrent Events (CARE) TrialAnnals of Internal Medicine, 1998